- Home
- KRYS vs ACT Comparison
KRYS vs ACT Comparison
Compare KRYS & ACT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KRYS | ACT |
|---|---|---|
| Founded | 2015 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Specialty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 5.6B |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | KRYS | ACT |
|---|---|---|
| Price | $279.47 | $39.25 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 3 |
| Target Price | ★ $250.50 | $41.00 |
| AVG Volume (30 Days) | ★ 299.1K | 250.3K |
| Earning Date | 02-18-2026 | 02-03-2026 |
| Dividend Yield | N/A | ★ 2.13% |
| EPS Growth | ★ 275.72 | 1.64 |
| EPS | ★ 6.66 | 4.36 |
| Revenue | $373,164,000.00 | ★ $1,224,897,000.00 |
| Revenue This Year | $36.14 | $4.60 |
| Revenue Next Year | $42.38 | $3.58 |
| P/E Ratio | $41.84 | ★ $9.06 |
| Revenue Growth | ★ 54.51 | 2.40 |
| 52 Week Low | $122.80 | $31.28 |
| 52 Week High | $295.98 | $41.35 |
Technical Indicators
Market Signals| Indicator | KRYS | ACT |
|---|---|---|
| Relative Strength Index (RSI) | 62.12 | 50.04 |
| Support Level | $275.00 | $38.46 |
| Resistance Level | $294.64 | $39.75 |
| Average True Range (ATR) | 11.68 | 0.89 |
| MACD | -0.51 | -0.06 |
| Stochastic Oscillator | 68.67 | 46.11 |
Price Performance
Historical ComparisonAbout KRYS Krystal Biotech Inc.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
About ACT Enact Holdings Inc.
Enact Holdings Inc is a private mortgage insurance company serving the United States housing finance market. The principal mortgage insurance customers are originators of residential mortgage loans who determine which mortgage insurer or insurers will be used for the placement of mortgage insurance written on loans originated. The company is engaged in writing and assuming residential mortgage guaranty insurance.